EMLA Cream for Pain Management in Subcutaneous Erythropoietin Administration

Evidence and Recommendations

The American Academy of Pediatrics supports the use of topical lidocaine-prilocaine emulsion (EMLA) for reducing pain associated with subcutaneous injections, noting it causes superficial anesthesia 1, 2
The American Academy of Pediatrics recommends avoiding the use of EMLA in infants <12 months receiving methemoglobin-inducing agents due to risk of methemoglobinemia 1, 2

Apply EMLA cream at least 60 minutes before injection under an occlusive dressing for adequate anesthesia 3, 4
Avoid using EMLA in patients with known allergy to amide anesthetics 3, 4
Contraindicated in patients with recent sulfonamide antibiotic use or congenital/idiopathic methemoglobinemia 3, 4
Exercise extreme caution in children under 12 months or weighing less than 10 kg, using reduced doses 3, 4

Subcutaneous administration of erythropoietin is the preferred route for chronic kidney disease and peritoneal dialysis patients, as it is more effective than intravenous administration and requires lower doses 5, 6
The typical subcutaneous erythropoietin dose for adults is 80-120 units/kg/week in 2-3 divided doses 5, 6
Ibuprofen or other non-aspirin analgesics can be used if needed, avoiding acetaminophen due to methemoglobin interaction concerns 1, 2
Liposomal 4% lidocaine cream (LMX4) provides anesthesia in approximately 30 minutes if time is limited, though this has not been specifically studied with erythropoietin 3